Deutsche Bank Maintains Hold Rating On Amylin

According to Deutsche Bank, Amylin Pharmaceuticals AMLN Hold rating is maintained. Deutsche Bank said that Amylin just announced that the FDA-required tQT study demonstrated that exenatide at and above therapeutic levels did not prolong QTc interval in healthy volunteers. “We currently believe AMLN shares are fairly valued at our $14 target price.” Amylin Pharmaceuticals closed yesterday at $13.44.